Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Fig. 3

Antitumor Activity of IT1208. a Waterfall plot of maximum tumor change from baseline in each patient. GC, gastric cancer; CRC, colorectal cancer; EC, esophageal cancer; PC, pancreatic cancer. b Spider plot of each patient. c Representative case with antitumor response. Case 10 had colorectal cancer with liver and lung metastases. This patient had been previously treated with fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, and panitumumab and then progressed. The patient experienced a PR (32% shrinkage of target lesions) at 2 months after IT1208 treatment. Tumor responses were maintained for more than 3 months at the data cutoff. Case 3 with esophageal squamous cell carcinoma also showed tumor shrinkage (21%), being disease free for 3.1 months

Back to article page